Semaglutide's Trial Data Is Genuinely Remarkable — And the Legal Ground Just Shifted Under the Research-Labeled Version
SELECT showed semaglutide cut cardiovascular death, heart attack, or stroke by 20% in a 17,604-person trial. Real, landmark data — but since February 2025 the FDA pulled the legal cover compounders were using to sell it, and Novo Nordisk has filed 14 lawsuits in a single week to enforce that.
Semaglutide became a household name through Ozempic and Wegovy, and most of the online conversation about it has flattened into either "miracle drug" or "just for weight loss" — both of which skip past what the actual trial data shows, and past a real legal shift that happened to the research-labeled version of this compound within the last year.
The Real Numbers
- STEP 1 (NEJM, 2021, 1,961 participants): 68 weeks of weekly 2.4mg semaglutide produced 14.9% average weight loss versus 2.4% on placebo. 86.4% of participants lost 5% or more of body weight, versus 31.5% on placebo.
- STEP 5 (2-year extension of the same program): the effect held — 15.2% average weight loss versus 2.6% on placebo at the two-year mark, not a short-term spike that fades.
- SELECT (NEJM, 2023, 17,604 adults with obesity and existing cardiovascular disease, no diabetes): semaglutide reduced the combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke by roughly 20% relative to placebo. This is the first trial of this scale to show a GLP-1 drug directly reducing cardiovascular events, not just moving the scale.
In December 2025, the FDA approved a once-daily oral 25mg tablet (oral Wegovy) for weight management — the first oral GLP-1 approved for that use, built on a trial program showing 16.6% average weight loss with adherence.
What Changed Legally in 2025
Here is the part that gets skipped in most coverage. On February 21, 2025, the FDA removed semaglutide from its official drug shortage list. While it was on that list, compounding pharmacies had a real legal basis to manufacture and sell compounded versions to fill the supply gap. Once it came off, that legal cover disappeared.
Novo Nordisk moved fast: in a single week in August 2025, it filed 14 lawsuits against compounding pharmacies and telehealth companies selling products marketed as "semaglutide" without FDA approval. This is not a settled or historical dispute — it is an active legal fight, and at least one compounding pharmacy (Strive Specialties) has countersued, alleging Novo Nordisk struck illegal agreements with telehealth companies to block compounders out entirely.
The Caveat That Matters
Every number in the first section above comes from the FDA-approved, pharmacy-dispensed product, manufactured to a validated purity and concentration standard, reached through a supervised titration schedule. None of it transfers automatically to a "research-labeled" vial from an unregulated seller. Same molecule name on the label does not mean the same purity, concentration, or manufacturing standard the trial data was actually generated on — and as of last year, selling that unregulated version is also squarely in a company's active litigation crosshairs, not just a regulatory gray area.